Heat Biologics, Inc. (NASDAQ:HTBX) saw strong trading volume on Thursday . 1,775,400 shares were traded during mid-day trading, an increase of 248% from the previous session’s volume of 510,629 shares.The stock last traded at $0.42 and had previously closed at $0.40.

The company has a market cap of $14.67, a P/E ratio of -0.98 and a beta of 0.69.

Heat Biologics (NASDAQ:HTBX) last posted its earnings results on Monday, November 13th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.03. Heat Biologics had a negative net margin of 1,184.92% and a negative return on equity of 149.69%. The firm had revenue of $0.47 million during the quarter, compared to the consensus estimate of $0.50 million. analysts anticipate that Heat Biologics, Inc. will post -0.35 EPS for the current year.

An institutional investor recently raised its position in Heat Biologics stock. Vanguard Group Inc. increased its position in Heat Biologics, Inc. (NASDAQ:HTBX) by 11.9% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 661,388 shares of the biopharmaceutical company’s stock after acquiring an additional 70,290 shares during the quarter. Vanguard Group Inc. owned about 1.86% of Heat Biologics worth $403,000 at the end of the most recent quarter. Institutional investors and hedge funds own 7.97% of the company’s stock.

WARNING: This piece of content was originally posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://www.dailypolitical.com/2018/01/11/heat-biologics-htbx-sees-strong-trading-volume.html.

Heat Biologics Company Profile

Heat Biologics, Inc is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT).

Receive News & Ratings for Heat Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics and related companies with MarketBeat.com's FREE daily email newsletter.